Liver-Directed AAV Vectors Inducing Antigen-Specific Tregs for MS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods lack effective viral vector-based treatments for autoimmune diseases such as multiple sclerosis (MS), particularly in inducing antigen-specific immune tolerance and suppressing immune responses in the central nervous system.
Innovation Solution
Development of novel adeno-associated virus (AAV) nucleic acid vectors optimized for liver-directed expression of neuroproteins like MOG, PLP, and MBP, which induce antigen-specific Tregs, reducing the need for identifying HLA-MHC-specific epitopes and promoting universal applicability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional gene therapy methods are used to treat autoimmune diseases, then some immune modulation may be achieved, but they fail to induce antigen-specific immune tolerance and suppress immune responses in the CNS
Solution Approach 1:
The patent uses AAV vectors as intermediaries to deliver neuroprotein antigens (MOG, PLP, MBP) to the liver, where they are processed and presented to the immune system. This intermediary approach allows the liver to generate antigen-specific Tregs that can then suppress CNS inflammation, solving the problem of inducing specific immune tolerance without directly targeting the CNS
Solution Approach 2:
The liver's natural immune processing functions are harnessed to generate antigen-specific regulatory T cells. By expressing full-length neuroproteins in the liver, the body's own immune system is directed to develop tolerance to these self-antigens, enabling the system to self-regulate the autoimmune response without external intervention in the CNS
2Reliability
If HLA-MHC-specific epitopes are used for treatment, then antigen-specific Tregs can be induced, but the need to identify specific epitopes limits universal applicability
Solution Approach 1:
The patent expresses full-length neuroproteins (MOG, PLP, MBP) that contain multiple potential epitopes, allowing the liver to present various antigen fragments to different T cell receptors. This universal approach eliminates the need to pre-identify HLA-MHC-specific epitopes, as the complete protein sequences naturally accommodate diverse human leukocyte antigen types, making the therapy universally applicable across different patients
Solution Approach 2:
Instead of selecting specific epitopes to fit HLA molecules, the patent inverts the approach by using full-length proteins that naturally contain multiple epitopes suitable for various HLA types. This reversal of the selection process simplifies the therapy design and enhances universal applicability
3Duration of action of stationary object
If AAV vectors are used for liver-directed gene therapy, then persistent expression of neuroproteins is achieved, but the complexity of vector design and production increases
Solution Approach 1:
The patent optimizes AAV vector parameters including selecting specific serotypes (AAV2, AAV8, AAV9) with different tropism profiles, adjusting promoter elements for liver-specific expression, and modifying capsid sequences to enhance liver targeting. These parameter changes achieve persistent neuroprotein expression in the liver while systematically managing the complexity through standardized vector design protocols
Data Source
AI summary
Disclosed are AAV viral-based vector compositions useful in delivering a variety of nucleic segments, including those encoding therapeutic polypetides to selected mammalian host cells for use in therapeutic autoimmune modalities, including, for example, the in vivo induction of immunological tolerance via a liver-directed AAV-based gene therapeutic regimen for treating and/or ameliorating autoimmune disorders such as multiple sclerosis.